INmune Bio shares rise 12.5% after-hours as Maxim Group analyst maintains Buy rating and $8.00 price target.

INmune Bio surged 12.5% in after-hours trading after Maxim Group analyst Jason McCarthy maintained a Buy rating with an $8.00 price target, citing the company's undervalued pipeline and 2026 clinical milestones as key catalysts. The analyst's reaffirmation of confidence in Inmune Bio's development trajectory likely spurred investor optimism, aligning with the stock's upward movement in the post-market session.